Bacterial lipopolysaccharide and Gram-negative bacterial surface antigens (LPS)

Bacterial lipopolysaccharide (LPS) and other Gram-negative surface antigens are critical structural components of the outer membrane of Gram-negative bacteria, serving as a protective barrier against environmental stressors and host immune factors (NIH, 2023). LPS is a complex glycolipid consisting of three regions: the toxic Lipid A moiety, a core oligosaccharide, and the highly variable O-antigen polysaccharide (Wikipedia, 2024). These molecules function as potent pathogen-associated molecular patterns (PAMPs) that are recognized by the host's innate immune system, primarily through the Toll-like receptor 4 (TLR4) complex (PubMed, 2022). While this recognition is vital for initiating an immune response, the systemic release of LPS during severe infections can trigger an overwhelming inflammatory cascade, leading to sepsis and septic shock (StatPearls, 2023). Therapeutic strategies targeting these antigens include the use of polymyxin antibiotics, which bind to Lipid A to disrupt the bacterial membrane, and the development of neutralizing antibodies or small molecules designed to inhibit LPS-induced TLR4 signaling (PubChem, 2024). Additionally, surface antigens like the O-antigen are key targets for vaccine development to provide serotype-specific immunity against pathogens such as Salmonella and Vibrio cholerae (PubMed, 2021).

Other names

EndotoxinLipid AO-antigenGram-negative surface antigensPathogen-associated molecular patterns (PAMPs)Outer membrane proteins (OMPs)

Drugs targeting these antigens typically work by binding to and neutralizing the endotoxic activity of Lipid A, disrupting the bacterial outer membrane integrity, or blocking the interaction between LPS and the host TLR4/MD-2 receptor complex to prevent systemic inflammation.